Table 4 Time on treatment (months) of L1 treatment using Kaplan–Meier analysis, for the incident study cohort (patients with the start of any major depressive disorder episode within the study period, 1/1/2016–31/5/2018), n = 2553
From: Epidemiology of treatment resistant depression among major depressive disorder patients in Israel
L1 treatment | TRD | N | Number (%) discontinued | Median time on treatment (95% CI), months | % on treatment at 3Â months | % on treatment at 6Â months | % on treatment at 12Â months | Log rank P value |
|---|---|---|---|---|---|---|---|---|
SSRI monotherapy | No TRD | 911 | 884 (97.04%) | 7.27 (6.08, 8.61) | 65.2% | 53.4% | 25.7% |  < 0.0001 |
TRD | 268 | 268 (100.00%) | 2.04 (1.87, 2.27) | 22.0% | 4.5% | 0.0% | ||
Total | 1179 | 1152 (97.71%) | 3.78 (3.32, 4.67) | 55.3% | 42.2% | 19.8% | Â | |
Other monotherapy | No TRD | 573 | 554 (96.68%) | 5.23 (4.24, 7.1) | 60.4% | 48.2% | 27.2% |  < 0.0001 |
TRD | 177 | 177 (100.00%) | 2.07 (1.91, 2.33) | 28.3% | 7.9% | 0.0% | ||
Total | 750 | 731 (97.47%) | 3.22 (2.96, 3.95) | 52.8% | 38.7% | 20.8% | Â | |
Combination therapy | No TRD | 393 | 376 (95.67%) | 9.50 (7.63, 10.65) | 70.2% | 58.7% | 31.6% |  < 0.0001 |
TRD | 156 | 156 (100.00%) | 2.32 (2.01, 2.63) | 30.1% | 6.4% | 0.0% | ||
Total | 549 | 532 (96.90%) | 4.11 (3.48, 5.26) | 58.8% | 43.8% | 22.6% | Â | |
TCA monotherapy | No TRD | 52 | 52 (100.00%) | 2.25 (0.99, 8.12) | 42.3% | 36.5% | 21.2% | 0.013 |
TRD | 23 | 23 (100.00%) | 1.91 (1.18, 3.48) | 30.4% | 4.4% | 0.0% | ||
Total | 75 | 75 (100.00%) | 2.17 (1.05, 3.32) | 38.7% | 26.7% | 14.7% | Â | |
Overall | No TRD | 1929 | 1866 (96.73%) | 6.97 (6.12, 8.19) | 64.1% | 52.5% | 27.2% |  < 0.0001 |
TRD | 624 | 624 (100.00%) | 2.07 (1.97, 2.27) | 26.1% | 5.9% | 0.0% | ||
Total | 2553 | 2490 (97.53%) | 3.65 (3.29, 3.98) | 54.8% | 41.1% | 20.5% | Â |